New diabetes treatment gets 'landmark' approval for NHS
The National Health Service (NHS) in England and Wales has approved a groundbreaking treatment for type 1 diabetes, marking a significant milestone in the fight against the condition. The drug, called teplizumab, is the first of its kind to delay the onset of type 1 diabetes for up to three years. This approval comes after extensive review by the National Institute for Health and Care Excellence (Nice), which deemed the treatment both effective and beneficial for patients.
The approval process began with the recognition that type 1 diabetes, which affects millions globally, typically manifests during childhood or adolescence. The disease occurs when the body's immune system mistakenly attacks the insulin-producing cells in the pancreas, leading to a reliance on insulin therapy. Traditional treatments involve insulin replacement, which has remained largely unchanged since its discovery over a century ago. Teplizumab, however, offers a novel approach by targeting the underlying autoimmune response that causes the disease.
Teplizumab is an immunotherapy developed by Sanofi, and it works by modulating the immune system to prevent it from attacking the pancreatic cells. The treatment involves a series of intravenous infusions lasting 14 days, with the dosage increasing gradually throughout the course. After completing the treatment, patients remain free from the immediate effects of the disease for several years, allowing them to avoid the burdensome daily management of diabetes for a prolonged period.
This new treatment is particularly promising for individuals identified as being at high risk of developing symptomatic type 1 diabetes, specifically those in the early, pre-symptomatic stages (stage 2). The approval extends to adults and children aged eight and older, providing a crucial opportunity for early intervention. The ability to delay the onset of the disease means that affected individuals can enjoy additional years of life without the constant monitoring and administration of insulin required for managing the condition.
The significance of this approval is underscored by the efforts of numerous organizations and individuals dedicated to advancing diabetes care. Charities such as Diabetes UK and Breakthrough T1D have played pivotal roles in advocating for the development and accessibility of this treatment. Their representatives expressed optimism about the potential impact of teplizumab, emphasizing that it represents a major leap forward in the treatment landscape for type 1 diabetes.
The approval also highlights the importance of early detection and intervention. While routine screening for type 1 diabetes is not currently available on the NHS in the UK, some families discover their risk through genetic predisposition or incidental blood tests conducted for other conditions. In Italy, a national screening program exists for children and young people, offering a model for potential future initiatives in the UK.
As the treatment becomes available, there is anticipation for its widespread adoption and integration into standard care protocols. Patients and caregivers alike are hopeful that teplizumab will provide much-needed relief and improved quality of life for those living with type 1 diabetes. With ongoing advocacy and continued research, the hope is that this treatment will pave the way for even greater advancements in the prevention and management of type 1 diabetes in the coming years.
4 reports
The Guardian (UK)IndependentCenterFactual 100Objective 9013 days agoA groundbreaking drug called teplizumab has been approved for use in England and Wales to delay the onset of type 1 diabetes, marking the first major advancement in treating the condition in over a century. Type 1 diabetes typically develops in childhood or adolescence and occurs when the pancreas produces little or no insulin. Teplizumab, an immunotherapy developed by Sanofi, does not cure the disease but can postpone its onset for up to three years. This treatment is intended for individuals identified as being at high risk of developing symptomatic type 1 diabetes (stage 3) and those in the early, pre-symptomatic stage (stage 2). The drug works by training the immune system to stop attacking pancreatic cells, allowing patients additional time before they must manage the condition with insulin. Experts describe this development as a significant milestone, offering hope for improved quality of life and potentially paving the way for prevention strategies.
Bias read (Center): The article discusses a medical advancement related to a health condition and focuses on scientific developments, approvals, and patient outcomes. There is no mention of political figures, policies, or contentious issues, making the content apolitical.
Why these scores (Factual 100 · Objective 90): Fully accurate with specific details like teplizumab, NICE approval, and patient benefits. Well-balanced with quotes from experts and clear distinction between type 1 and 2 diabetes. Slight emotional appeal in quotes but overall neutral.
BBC News (UK)State / PublicCenterFactual 100Objective 8814 days agoThe first drug capable of delaying the onset of type 1 diabetes, teplizumab, has been approved for use on the NHS in England and Wales. This immunotherapy treatment can provide individuals with up to three additional years before they develop symptoms requiring lifelong insulin therapy. The NHS described the approval as 'genuinely exciting,' noting that hundreds of children and young people could benefit annually. Type 1 diabetes occurs when the immune system attacks insulin-producing cells in the pancreas, unlike type 2 diabetes, which is often linked to obesity. Theo Sebastian-Jenkins, who was diagnosed with type 1 diabetes at age four, is now eight and manages his condition through careful monitoring of diet and blood sugar levels. His family highlights the potential impact of teplizumab, emphasizing how it could offer relief to families by providing three more years of childhood without the burdens of managing the disease.
Bias read (Center): The article focuses on a health-related development involving a new medical treatment for type 1 diabetes. It provides balanced information about the drug's benefits, mechanism of action, and patient experiences without showing clear ideological bias. There is no mention of political figures, policy
Why these scores (Factual 100 · Objective 88): Accurate with full details on teplizumab, NICE approval, and patient impact. Includes personal stories which add context but may slightly reduce objectivity. Still largely neutral and informative.
BBC News (UK)State / PublicCenterFactual 100Objective 8714 days ago First drug to delay onset of type 1 diabetes made available on NHSThe first drug capable of delaying the onset of type 1 diabetes, teplizumab, has been approved for use on the NHS in England and Wales. This immunotherapy treatment can provide individuals with up to three additional years before they develop symptoms requiring lifelong insulin therapy. The NHS described the approval as 'genuinely exciting,' noting that hundreds of children and young people could benefit annually. Type 1 diabetes occurs when the immune system attacks insulin-producing cells in the pancreas, unlike type 2 diabetes, which is often linked to obesity. Patients and advocacy groups highlight the significance of this development, emphasizing the potential relief for families managing the condition. Theo Sebastian-Jenkins, who was diagnosed with type 1 diabetes at age four, is now eight and benefits from careful management of his condition, though he was too young to receive the new drug at the time of his diagnosis.
Bias read (Center): The article focuses on a health-related scientific advancement with no direct political implications. It provides balanced information about the drug's mechanism, patient experiences, and expert opinions without showing bias toward any political stance.
Why these scores (Factual 100 · Objective 87): Same content as item 2, with identical facts and similar level of objectivity. Personal story included, which adds human interest but slightly reduces neutrality.
Sky News (UK)IndependentCenterFactual 95Objective 8513 days agoA new therapy that can delay the onset of type 1 diabetes for up to three years has received approval for use within the UK National Health Service (NHS). This treatment represents a significant advancement in diabetes management, offering patients a potential delay in disease progression. The approval suggests that the NHS recognizes the therapeutic value of this innovation, which could impact future healthcare strategies for managing type 1 diabetes.
Bias read (Center): The article discusses a medical breakthrough with no direct political implications or controversy. It focuses on health advancements and does not present any biased framing or political commentary.
Why these scores (Factual 95 · Objective 85): Factual claims align closely with other sources, accurately stating the approval of a new treatment. Slightly less detailed than others but still accurate. Objectivity is good but slightly promotional tone with 'landmark' suggests some bias.
★
Keep the news honest.
ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €5/month.
Become a Supporter
United Kingdom
